Sage Therapeutics and Biogen's Phase 2 KINETIC 2 study for essential tremor treatment with SAGE-324 failed, causing stock collapse.

Sage Therapeutics and Biogen's Phase 2 KINETIC 2 study for essential tremor treatment failed, causing Sage's stock to collapse. The drug, SAGE-324, did not show a statistically significant improvement in tremor or activities of daily living among patients. Both companies have decided to halt the ongoing study and consider potential alternative uses for the drug.